Europe’s new Health Technology Assessment Regulation (HTAR) on the horizon
In early 2025, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR), addressing disparities in evaluating the clinical value of pharmaceuticals and medical devices.
The HTAR introduces a Joint Clinical Assessment (JCA) across the continent, a framework mandating that all 27 Member States adopt standardised procedures for evaluating the clinical evidence of newly submitted products or devices.
This special report looks at the opportunities, concerns, stakeholders’ readiness and ongoing administrative complexities.
-
Inclusivity, transparency, delivery – navigating the EU’s new Health Technology Assessment Regulation (HTAR)
News | Health 21-03-2024
Est. 7min
The EFPIA HTA Working Group’s Inka Heikkinen and James Ryan spoke with Euractiv’s Nicole Verbeeck, giving insights on moving towards a robust HTA system – one that serves patients, industry and progress in Europe or member states.
-
Under pressure, stakeholders preparing for EU’s new Health Technology Assessment Regulation
News | Advocacy Lab Content | Health 21-03-2024
Est. 5min
Within a year, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR). Concerns remain about stakeholders’ readiness and administrative complexities.
